Champions Oncology (NASDAQ:CSBR) and Nightstar Therapeutics (NASDAQ:NITE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
Insider & Institutional Ownership
52.8% of Champions Oncology shares are owned by institutional investors. Comparatively, 32.8% of Nightstar Therapeutics shares are owned by institutional investors. 44.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Champions Oncology and Nightstar Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Champions Oncology and Nightstar Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Champions Oncology currently has a consensus price target of $14.50, suggesting a potential upside of 82.16%. Nightstar Therapeutics has a consensus price target of $27.08, suggesting a potential upside of 6.55%. Given Champions Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Champions Oncology is more favorable than Nightstar Therapeutics.
Risk and Volatility
Champions Oncology has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Nightstar Therapeutics has a beta of 2.84, indicating that its stock price is 184% more volatile than the S&P 500.
Earnings & Valuation
This table compares Champions Oncology and Nightstar Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Champions Oncology||$20.24 million||4.57||-$1.47 million||($0.14)||-56.86|
|Nightstar Therapeutics||N/A||N/A||-$36.86 million||($1.26)||-20.17|
Champions Oncology has higher revenue and earnings than Nightstar Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Nightstar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Champions Oncology beats Nightstar Therapeutics on 9 of the 12 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.